Budget impact of introducing an omalizumab biosimilar in 23 European countries
Adopting an omalizumab biosimilar in European healthcare systems could yield substantial cost savings, enhance patient access, and reduce fiscal pressure. This analysis supports biosimilars as a strategic tool for sustainable biologic therapy access in Europe.
Authors
- Shuhua Yi (ORCID: https://orcid.org/0000-0002-6291-812X)
- Minyoung Jang (ORCID: https://orcid.org/0000-0001-5145-297X)
- Jooyeop Lee
- Taek Sang Kwon
Institutions
- Celltrion (South Korea) (KR)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-09-16
- DOI
- https://doi.org/10.1080/13696998.2025.2558450
- Citations
- 2
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 1.59